For the surgical treatment of gastric cancer with curative intent, two issues are of main importance: the radical removal of the tumor and the radical removal of affected lymph nodes.
For radical removal of the tumor, margins up to 8 cm for diffuse-type carcinoma (German guidelines) are advised because microscopic positive resection margins lead to poor prognosis [1] . In a comparative study of 619 patients, it was shown that intraoperative re-excision of microscopically involved resection margins may be beneficial for patients with less than five affected lymph nodes [2] .
When Billroth performed his first gastric resection in 1881, he actually also removed some enlarged nodes. His patient died 14 months after the operation of recurrent disease. Since then, the extent of lymph node dissection has been an issue in the treatment of gastric cancer. Theoretically, removal of a wide range of lymph nodes improves the chances for cure. Such resection, however, could be irrelevant when no lymph nodes are affected, or when the cancer has developed into systemic disease, or the dissection increases morbidity and mortality substantially.
From randomized studies, nowadays a D2 lymph node dissection is advised [3] . More extended lymph node dissections did not lead to improved survival, as shown by Sasako et al. [4] , in a randomized D2 versus D4 trial in Japan.
One of the main problems in the Western D1-D2 trials was the occurrence of major complications in the D2 dissection group, mostly caused by pancreatico-splenectomy. The increased morbidity and mortality in the D2 group probably offset the survival gain at that time. Subgroup analysis from the Dutch gastric cancer trial of patients who did not undergo a pancreatico-splenectomy showed a significant survival advantage for those who had a D2 lymph node dissection (11-year survival, 33 % for D1 and 47 % for D2; p = 0.018) [3] . In a late follow-up study it was shown that local recurrence rate and cancer-related death were significantly higher in the D1 dissection group as compared to the D2 dissection group [5] .
To make lymph node dissections more 'tailor made,' Prof. Maruyama introduced the Maruyama index of unresected disease [6] . Based on seven input variables (age, sex, Borrman type, tumor size, tumor position, and histology), the likelihood for nodal involvement can be calculated. The chance of affected lymph nodes along the splenic artery (station no. 11) and the splenic hilum (no. 10) is highest is patients with large, proximal, poorly differentiated tumors. For adequate removal of these lymph node stations, a splenectomy is often performed.
Another way to individualize gastric cancer treatment is the use of the index of estimated benefit from lymph node dissection (IEBLD) [7] . This index is calculated by multiplying the frequency of lymph node metastasis to each station by the 5-year survival rate of patients with positive lymph nodes at each station.
To evaluate the effect of splenectomy for gastric cancer, three randomized trials have been performed in the past. In these randomized trials from Chile [8] , Korea [9] , and Japan [10] , researchers reported no survival benefit from splenectomy in patients with a total gastrectomy, whereas morbidity was increased. A meta-analysis of operative survival with the data from these randomized trials showed no statistically significant difference (OR, 1.59; 95 % CI, 0.44-5.79) [11] . A large randomized trial to evaluate the use of splenectomy in gastric cancer is currently underway in Japan [12] .
A systematic review of spleen and pancreas preservation in extended lymphadenectomy for gastric cancer was recently presented in Gastric Cancer by Brar et al. [11] . From this analysis it is concluded that ''despite the concern about the increased morbidity and mortality of splenectomy and distal pancreatectomy during extended lymphadenectomy for gastric cancer as demonstrated in some studies, more contemporary studies demonstrate that this procedure can still be done safely with low short-term morbidity and mortality for patients undergoing curative surgery for gastric cancer.'' However, in the studied randomized controlled trials, no difference in 5-year survival was found. Preservation of the spleen and pancreas during extended lymphadenectomy may therefor decrease complications with no detriment effect on overall survival.
Several studies have focused on the effect of splenectomy on survival for proximal gastric cancer.
Sasada et al. [13] retrospectively evaluated 349 patients who underwent a total gastrectomy for proximal gastric cancer. In 201 patients the splenic hilus was histologically assessed and contained metastatic lymph nodes in 15.4 % of cases. They found no lymph node metastasis in the splenic hilus for T1 and T2 tumors located in the lesser curvature. Five-year survival for those with affected lymph nodes in the splenic hilus was only 15 % as compared to 49 % (p \ 0.001) for those without metastatic lymph nodes in the splenic hilus.
Kodera et al. [14] retrospectively analyzed 224 patient who had a D2 dissection for proximal gastric cancer. Splenectomy was performed in 129 patients (57 %) and pancreatico-splenectomy in 38 (17 %). Morbidity and mortality were significantly increased in these groups, especially the pancreatico-splenectomy group. Survival, however, was substantially decreased if patients had metastatic lymph nodes in station 10 or 11, with an IEBLD of 3.8 and 3.4, respectively.
The clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer was also studied by Shin et al. [15] . In 41 of 319 patients (12.9 %), splenic hilar lymph node metastases were found, mostly in patients with large, poorly differentiated tumors. Patients with early gastric cancer did not have splenic hilar lymph node metastasis. The 5-year survival was 11 % for the hilar metastasis group (p \ 0.001), which was significantly lower than in the non-metastasis group, in which it was 51.5 %. Multivariate analysis revealed that hilar metastasis was an independent prognostic factor (HR, 1.671; 95 % CI, 1.075-2.595; p = 0.022). The effectiveness of prophylactic splenectomy is therefore questioned by this study group.
Whether splenectomy is of value in gastric cancer located at the esophagogastric junction (EGJ) (i.e., Siewert II) is not known.
In this issue of Gastric Cancer, the retrospective study of Goto et al. [16] is presented in which the value of splenectomy in patients with type II adenocarcinoma of the ECJ is evaluated. In this study, 4.8 % of the 42 evaluated patients had lymph node involvement in the splenic hilum. None of these patients survived for 5 years. The calculated IEBLD for lymph node stations 10 and 11d was therefore zero. Morbidity consequent to the splenectomy occurred in nearly 60 % of patients. From this study it was concluded that splenic hilus lymph node dissection may be omitted without decreasing curability in patients with Siewert type II adenocarcinoma of the EGJ.
One other study has evaluated the optimal extent of lymph node dissection for Siewert type II EGJ carcinoma. Yamashita et al. [17] evaluated 225 patients with Siewert type II tumors retrospectively. They found that the incidence of nodal metastasis was highest in the right paracardial (38.2 %), the lesser curvature (35.1 %), the left paracardial (23.1 %), and the nodes along the left gastric artery (20.9 %). Nodes along the distal splenic artery (station 11d) and the splenic hilus (station 10) were found in 18 patients (8 %). In 25 patients (11 %) the proximal splenic artery lymph nodes (station 11p) were affected. Five-year survival for patients with metastatic nodes in the splenic hilus was 16.7 %. An IEBLD of 0.7 was calculated. From this study it was concluded that dissection of the paracardial and lesser curvature nodes is deemed to be essential for staging as well as treatment in surgery for EGJ carcinomas. Furthermore, the removal of splenic hilus lymph nodes can hardly be justified by this study.
So, in conclusion: several studies have evaluated the ''costs'' and benefits of (pancreatico-)splenectomy for gastric cancer. All studies have in common that prognosis for patients with affected lymph nodes in the splenic hilus is very poor. This finding also accounts for more specified evaluations of patients with proximal gastric carcinoma and those with Siewert type II EGJ adenocarcinomas.
Although more recent studies demonstrate that (pancreatico-)splenectomy can be done safely, the procedure still leads to an increased morbidity and mortality. Therefore, I think that the removal of splenic hilus lymph nodes should not be performed, even in esophagogastric junction adenocarcinoma, and that (pancreatico-)splenectomy is only justified in cases with direct ingrowth into the spleen or pancreatic tail.
